Industry Notes / Pharma / Chapter 1 of 20 · Thesis cards
Of the ten conclusions, keep these five first
Pharma’s ceiling is set by payers, not by science
The profit pool is in the US
Global drug market ~$1.7 tn. Tiny population, huge spend—profit follows the payer.
US drug-price shocks move the whole industry’s valuation center.
US pricing is being rewritten
The US premium was put on the negotiating table as a system.
Not one headline—the profit base is being rewritten.
A super winner is a five-factor product
Need × edge × patents × own commercial × deep focus
The right category is not enough; one zero zeros the formula.
Going overseas is arithmetic
The same molecule meets a much larger payer.
A domestic peak is often a fraction of US value.
Discount the headline total
2026H1 out-licensing: big headline, small cash.
Give hard value only to upfront and already-hit milestones.
These five lines are the reading lens for the whole book. Later chapters expand one judgment each. The numbers are anchors, not full statements.
Source：IQVIA Early Bird（2026-03）；白宫 Fact Sheet / MFN；医药魔方；WHO / 国家卫健委卫生费用通行口径
Research notes, not investment advice.